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| INTRODUC TI ON
Bladder cancer is one of the leading urogenital malignancies worldwide. Approximately 70% of diagnoses of bladder cancer are initially detected as a nonmuscle-invasive superficial disease, classified as stages Ta, T1, or carcinoma in situ (CIS). 1 In the clinical setting, NMIBC is treated with a combination of transurethral resection of the bladder tumor and intravesical chemotherapy. However, approximately half of the patients experience tumor recurrence because of remnant tumor cells and limited chemotherapy effects. 2 In addition, the mechanism underlying the bladder cancer cells' proliferation remains unclear, thereby highlighting the necessity of exploring innovative approaches to suppress cancer cell proliferation and enhance curative effects in bladder cancer treatment.
Tumor progression does not only depend on cancer cells' autonomous features and is related to several factors, including the activation of prosurvival signaling pathways in tumor cells, 3 intercellular cross-talk between cancer and stroma cells, 4, 5 and the immune microenvironment. 6, 7 Accumulating evidence suggests that TAMs in the tumor microenvironment play a vital role in tumor growth. [8] [9] [10] [11] As one of the most crucial immune cells residing within the tumor microenvironment, TAMs constitute a subpopulation of immunosuppressive cells to avert the tumor cell attack by natural killer and T cells during tumor progression. 11, 12 Such TAMs are recruited by tumor cells and present at all stages of tumor progression, 13, 14 including tumor cell invasion, extravasation, survival, and persistent growth. 15, 16 However, the mechanism underlying TAM-induced tumor progression remains unclear, and the innovative approach to target those protumoral macrophages has been an attractive strategy as part of combination therapy in cancer therapy. 17, 18 Previously, we demonstrated that TAMs 17 
| MATERIAL S AND ME THODS

| Cell lines and reagents
We purchased DOX, MMC, and HCPT from Sangon Biotech (Shanghai, China). E7820, LY294002, and MK-2206 were purchased from Selleck Chemicals (Houston, TX, USA 
| Cell proliferation analysis and colony formation experiments
We detected cell proliferation using the MTT Analysis Kit (Solarbio, Beijing, China 
| Flow cytometry
We added anti-CD68 (Abcam, Cambridge, UK), anti-F4/80 (Abcam), or CD206 (Abcam) Abs to the cell suspension to isolate TAMs in tumor tissues. After incubating for 30 minutes at room temperature, the samples were sorted by BD FACSAria III (BD Biosciences). The isotype was stained as a negative control.
| Real-time PCR
We used 1 μg cDNA as the template for the quantitative real-time PCR to detect the target genes (SYBR Green Real-Time PCR master mixes; Thermo Fisher Scientific, Waltham, MA, USA). Actin was used as the internal control, and 3 independent experiments were carried out in each sample. The relative expression was quantified by normalizing the target gene level to the actin by the ΔΔC t method. The primer pairs used are listed in Table S1 . 
| Western blot analysis
| Immunofluorescence staining
We fixed and permeabilized MB49 cells treated with collagen or E7820
to examine the PI3K/AKT signaling pathway in bladder cancer cells.
Then the cells were labeled with anti-integrin β1 ( 
| Immunohistochemistry
All tumor tissues were kept in 4% paraformaldehyde overnight, then processed, embedded in paraffin, and sectioned at 4 μm. The tumor sections were incubated with F4/80 (1:200; Abcam) or type I collagen (1:500; Abcam) at 4°C overnight, followed by signal amplification using the ABC HRP Kit (Thermo Fisher Scientific) and counterstaining with hematoxylin, dehydration with series of graded ethanol, and cleaned with xylene. We used a microscope (Leica) to visualize the sections.
| Enzyme-linked immunosorbent assay
The quantification of type I collagen in macrophage cultured medium was carried out with a type I collagen ELISA analysis kit (Kramer) as guided. One hundred microliters (10×) of macrophage cultured medium was used for the ELISA analysis. The assays used the quantitative sandwich enzyme immunoassay technique using murine collagen I with Abs raised against the recombinant proteins. Optical density was read with a microtiter plate reader by dual wavelength at 450 nm. All samples were assayed in duplicate.
| Animal protocol
We purchased female C57BL mice (6-8 weeks old) from Huafukang
Company (Beijing, China) and maintained them in specific 
| Statistical analysis
All data are presented as mean ± SEM. GraphPad Prism 6.0 (San Diego, CA) was used for statistical analysis (P < .05). We used Student's t test to analyze between-group differences. In addition, the survival analysis was carried out by the Kaplan-Meier method and evaluated using the log-rank test. We considered P < .05 as considered significant.
| RE SULTS
| Tumor-associated macrophages facilitate tumor growth in bladder cancer
To 
| Tumor-associated macrophages facilitate bladder cancer cell growth through secretion of collagen
We wondered how TAMs participated in tumor development in bladder cancer. Current knowledge suggests that TAMs can remodel Figure 2J ). Overall, these findings showed that collagen produced by TAMs promotes bladder cancer growth.
| Collagen promotes tumor growth through activation of the integrin α2β1/PI3K/AKT signaling pathway
Previously, we revealed that bladder cancer cells show a dramatic increase in expression of collagen receptor integrin β1 after TAMs coculture. Growing evidence suggests that integrin α1, α2, α10, and Error bars, mean ± SEM. *P < .05; **P < .01. n.s, not statistically significant α11 could combine with integrin β1 to form integrin heterodimers to regulate the downstream signaling pathway induced by collagen. 21 In addition, we determined the upregulation of integrin α2 in collagen-treated cancer cells ( Figure 3A) . Furthermore, we observed the upregulation of integrin α2β1 in the protein level in collagen-treated cancer cells, suggesting that integrin α2β1 participates in collageninduced tumor cell proliferation ( Figure 3B ). We used E7820, an integrin α2β1 inhibitor, which efficiently suppressed the expression of integrin α2 induced by collagen ( Figure S1F ) without influencing cell proliferation or colony formation ( Figure S1G ), to further verify our hypothesis and treat cancer cells and, subsequently, to detect collagen-induced proliferative effects. As anticipated, E7820 efficiently reversed the collagen-induced proliferative effects in bladder cancer cells (Figure 3C,D) . A similar result was observed in mice with orthotopic bladder tumors ( Figure 3E ). Overall, these findings suggested that collagen promotes bladder cancer growth through integrin α2β1.
As a classic downstream molecular pathway of the integrin β1 signaling axis, PI3K/AKT participates in various physiological activities, including cell cycle, metabolism, and sustained growth. [22] [23] [24] Previous studies reported that the PI3K/AKT signaling pathway is correlative in the sustained growth of various solid tumors. 25 Intriguingly, we observed enhanced phosphorylated PI3K and AKT in collagentreated MB49 cells, suggesting the activation of the PI3K/AKT signaling pathway ( Figure 4A,B) . In addition, we used LY294002 and MK2206, PI3K and AKT inhibitors, respectively, without effects on cell proliferation or colony formation ( Figure S1H ), to treat bladder cancer cells. We found that the blockade of PI3K/AKT signals effectively reversed the enhanced proliferative and colony-formation abilities induced by collagen ( Figure 4C-F) . Notably, similar results were observed in mice with orthotopic bladder tumors ( Figure 4G ).
These findings implied that collagen could activate the integrin α2β1/PI3K/AKT signaling pathway to facilitate bladder cancer cell proliferation.
| Combination of integrin α2β1 and chemotherapeutic agents revealed enhanced anticancer effects in vivo
Considering the proliferative effects induced by the integrin α2β1/ PI3K/AKT signaling pathway, we hypothesized that the combina- In conclusion, this study found that TAMs in tumor sites could facilitate bladder cancer proliferation by secreting collagen. Collagen activates the PI3K/AKT prosurvival signaling pathway. Furthermore, the combination of integrin α2β1 inhibitor and chemotherapeutic agents could be explored as a potential therapeutic strategy in bladder cancer.
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